Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats

Peptides

Volumn 32, Issue 4, 2011, Pages 755-762

  Agnew, A ^a   Calderwood, D ^a   Chevallier, O P ^a   Greer, B ^a   Grieve, D J ^b   Green, B D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Lipids; Obestatin; Peptide; Peptide analog; Triglycerides

Indexed keywords

CHOLESTEROL; GLUCOSE; MACROGOL; OBESTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DRUG STABILITY; FLUID INTAKE; FOOD INTAKE; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; CHROMATOGRAPHY, LIQUID; DRINKING BEHAVIOR; FEEDING BEHAVIOR; GHRELIN; MALE; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

RATTUS;

EID: 79952817575     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.12.005     Document Type: Article

References (43)

1. Bassil AK, Häglund Y, Brown J, Rudholm T, Hellström PM, Näslund E, et al. Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. Br J Pharmacol 2007;150:58-64. (Pubitemid 46094669)
2. Beasley JM, Ange BA, Anderson CA, Miller Iii ER, Holbrook JT, Appel LJ. Characteristics associated with fasting appetite hormones (obestatin, ghrelin, and leptin). Obesity 2009;17:349-54.
3. Bresciani E, Rapetti D,DonàF, Bulgarelli I, Tamiazzo L, Locatelli V, et al. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J Endocrinol Invest 2006;29:RC16-8.
4. Catalán V, Gómez-Ambrosi J, Rotellar F, Silva C, Gil MJ, Rodríguez A, et al. The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clin Endocrinol 2007;66:598-601. (Pubitemid 46434943)
5. Chartrel N, Alvear-Perez R, Leprince J, Iturrioz X, Reaux-Le Goazigo A, Audinot V, et al. Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". Science 2007;315:766.
6. Chen CY, Chien EJ, Chang FY, Lu CL, Luo JC, Lee SD. Impacts of peripheral obestatin on colonic motility and secretion in conscious fed rats. Peptides 2008;29:1603-8.
7. Egerod KL, Holst B, Petersen PS, Hansen JB, Mulder J, Hökfelt T, et al. GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol Endocrinol 2007;21:1685-98. (Pubitemid 47001091)
8. Fontenot E, DeVente JE, Seidel ER. Obestatin and ghrelin in obese and in pregnant women. Peptides 2007;28:1937-44. (Pubitemid 47419111)
9. Gao XY, Kuang HY, Liu XM, Ma ZB. Decreased gastric body mucosa obestatin expression in overweight and obese patients. Peptides 2010;31:291-6.
10. Germain N, Galusca B, Grouselle D, Frere D, Tolle V, Zizzari P, et al. Ghrelin/ obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. Psychoneuroendocrinology 2009;34:413-9.
11. Gourcerol G, Coskun T, Craft LS, Mayer JP, Heiman ML, Wang L, et al. Preproghrelin-derived peptide, obestatin, fails to influence food intake in lean or obese rodents. Obesity 2007;15:2643-52.
12. Grala TM, Kay JK, Walker CG, Sheahan AJ, Littlejohn MD, Lucy MC, et al. Expression analysis of key somatotropic axis and liporegulatory genes in ghrelinand obestatin-infused dairy cows. Domest Anim Endocrinol 2010;39:76-83.
13. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, et al. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 2008;57:967-79.
14. Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, et al. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biol Chem 2004;385:169-77. (Pubitemid 38461337)
15. Green BD, Irwin N, Flatt PR. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 2007;28:981-7.
16. Green BD, Irwin N, Flatt PR. Metabolic responses of obestatin peptides in normal and high-fat fed mice. Amino Acids 2009;37:9-19.
17. Green BD, Gault VA, O'Harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 2004;10:3651-62. (Pubitemid 39386580)
18. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007;92:1168-71. (Pubitemid 46465698)
19. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, et al. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 2007;148:13-20. (Pubitemid 46021433)
20. Kerr BD, Irwin N, Flatt PR, Gault VA. Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance. Peptides 2009;30:219-25.
21. Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP. Obestatin reduces food intake and suppresses body weight gain in rodents. Biochem Biophys Res Commun 2007;357:264-9. (Pubitemid 46574526)
22. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W. Obestatin does not activate orphanGprotein-coupled receptor GPR39. Biochem Biophys ResCommun 2006;351:21-5. (Pubitemid 44740415)
23. Li ZF, Guo ZF, Cao J, Hu JQ, Zhao XX, Xu RL, et al. Plasma ghrelin and obestatin levels are increased in spontaneously hypertensive rats. Peptides 2010;31:297-300.
24. Monteleone P, Serritella C, Martiadis V, Maj M. Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. Biol Psychiatry 2008;64:1005-8.
25. Nagaraj S, Peddha MS, Manjappara UV. Fragment analogs as better mimics of obestatin. Regul Pept 2009;158:143-8.
26. Nagaraj S, Peddha MS, Manjappara UV. Fragments of obestatin as modulators of feed intake, circulating lipids, and stored fat. Biochem Biophys Res Commun 2008;366:731-7.
27. Nakahara T, Harada T, Yasuhara D, Shimada N, Amitani H, Sakoguchi T, et al. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 2008;64:252-5. (Pubitemid 351927261)
28. Nogueiras R, Pfluger P, Tovar S, Arnold M, Mitchell S, Morris A, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 2007;148:21-6. (Pubitemid 46021434)
29. Roth CL, Reinehr T, Schernthaner GH, Kopp HP, Kriwanek S, Schernthaner G. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg 2009;19:29-35.
30. ScrimaM, Campiglia P, Esposito C, Gomez-Monterrey I, Novellino E, D'Ursi AM. Obestatin conformational features: a strategy to unveil obestatin's biological role? Biochem Biophys Res Commun 2007;363:500-5.
31. Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 2006;29:RC13-5.
32. Subasinghage AP, Green BD, Flatt PR, Irwin N, Hewage CM. Metabolic and structural properties of human obestatin {1-23} and two fragment peptides. Peptides 2010;31:1697-705.
33. Tang SQ, Jiang QY, Zhang YL, Zhu XT, Shu G, Gao P, et al. Obestatin: its physicochemical characteristics and physiological functions. Peptides 2008;29:639-45.
34. Tsubery H, Mironchik M, Fridkin M, Shechter Y. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J Biol Chem 2004;279:38118-24. (Pubitemid 39295957)
35. Unniappan S, Speck M, Kieffer TJ. Metabolic effects of chronic obestatin infusion in rats. Peptides 2008;29:1354-61.
36. Van Dijck A, Van Dam D, Vergote V, De Spiegeleer B, Luyten W, Schoofs L, et al. Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regul Pept 2009;156:77-82.
37. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides 2008;29:1740-8.
38. Vicennati V, Genghini S, De Iasio R, Pasqui F, Pagotto U, Pasquali R. Circulating obestatin levels and the ghrelin/obestatin ratio in obese women. Eur J Endocrinol 2007;157:295-301. (Pubitemid 47603533)
39. Zamrazilová H, Hainer V, Sedlácková D, Papezová H, Kunesová M, Bellisle F, et al. Plasma obestatin levels in normal weight, obese and anorectic women. Physiol Res 2008;57:S49-55.
40. Zhang JV, Jahr H, Luo CW, Klein C, Van Kolen K, VerDonck L, et al. Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol Endocrinol 2008;22:1464-75. (Pubitemid 351787005)
41. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005;310:996-9. (Pubitemid 41611907)
42. Zhou J, Cai ZH, Li L, Kou C, Gao YF. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichiapastoris. Eur J Pharm Biopharm 2009;72:412-7.
43. Zou CC, Liang L, Wang CL, Fu JF, Zhao ZY. The change in ghrelin and obestatin levels in obese children after weight reduction. Acta Paediatr 2009;98:159-65.